Results for "Immunosenescence Reversal" in Cancer

20 articles

Engineered Immune Cells Show Promise Against Advanced Cancer in Early Trial
Cancer Research

Engineered Immune Cells Show Promise Against Advanced Cancer in Early Trial

Scientists modified patients' immune cells to better recognize and attack cancer tumors expressing NY-ESO-1 protein.

Clinical Trial
Mar 28, 2026 0
Modified T Cells Show Promise Against Childhood Blood Cancers in NCI Trial
Cancer Research

Modified T Cells Show Promise Against Childhood Blood Cancers in NCI Trial

Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.

Clinical Trial
Mar 28, 2026 0
Enhanced CAR-T Cell Therapy Shows Promise Against Treatment-Resistant Blood Cancers
Cancer Research

Enhanced CAR-T Cell Therapy Shows Promise Against Treatment-Resistant Blood Cancers

Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.

Clinical Trial
Mar 29, 2026 12
PULSAR Radiation Plus IMSA101 Immunotherapy Trial in Oligoprogressive Cancers Terminated Early
Cancer Research

PULSAR Radiation Plus IMSA101 Immunotherapy Trial in Oligoprogressive Cancers Terminated Early

A Phase 2 trial combining adaptive stereotactic radiotherapy with IMSA101 and checkpoint inhibitors was halted after enrolling only 16 patients.

Clinical Trial
May 14, 2026 0
Trial Tests Whether Stopping Immunotherapy Early Harms NSCLC Patients Who Respond
Cancer Research

Trial Tests Whether Stopping Immunotherapy Early Harms NSCLC Patients Who Respond

A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.

Clinical Trial
Jun 14, 2026 0
Brain Cancer Trial Uses Patient's Own Tumor Cells to Train Immune System
Cancer Research

Brain Cancer Trial Uses Patient's Own Tumor Cells to Train Immune System

Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.

Clinical Trial
Mar 28, 2026 0
Melanoma Drug Resistance Linked to Cellular Communication Vesicles Called Exosomes
Cancer Research

Melanoma Drug Resistance Linked to Cellular Communication Vesicles Called Exosomes

French researchers studied how tiny cellular packages called exosomes may help melanoma cells resist treatment and spread throughout the body.

Clinical Trial
Mar 28, 2026 0
Strength Training Fights Inflammaging in Bone Marrow Transplant Survivors
Cancer Research

Strength Training Fights Inflammaging in Bone Marrow Transplant Survivors

A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.

Clinical Trial
May 25, 2026 0
High-Dose Radiation Therapy Study Reveals Immune System Response Patterns in Cancer
Cancer Research

High-Dose Radiation Therapy Study Reveals Immune System Response Patterns in Cancer

Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.

Clinical Trial
Mar 28, 2026 2
New Cancer Immunotherapy IBI346 Shows Promise in Multiple Myeloma Trial
Cancer Research

New Cancer Immunotherapy IBI346 Shows Promise in Multiple Myeloma Trial

Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.

Clinical Trial
Mar 28, 2026 1
Skin Microbiome Shifts Detected in Immunotherapy Rash Patients
Cancer Research

Skin Microbiome Shifts Detected in Immunotherapy Rash Patients

A City of Hope study explores whether skin bacteria differ between rash-affected and healthy skin in cancer immunotherapy patients.

Clinical Trial
Jun 6, 2026 0
Cancer Immunotherapy May Weaken Bones in Melanoma Survivors
Cancer Research

Cancer Immunotherapy May Weaken Bones in Melanoma Survivors

Study examines bone density loss in melanoma patients receiving immune-boosting cancer drugs like nivolumab and pembrolizumab.

Clinical Trial
Mar 29, 2026 1
Engineered T Cells Show Promise Against Childhood Cancers in Phase I Trial
Cancer Research

Engineered T Cells Show Promise Against Childhood Cancers in Phase I Trial

Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.

Clinical Trial
Mar 28, 2026 0
Whole-Cell Breast Cancer Vaccine Plus PD-1 Inhibitor Targets Treatment-Resistant Metastatic Disease
Cancer Research

Whole-Cell Breast Cancer Vaccine Plus PD-1 Inhibitor Targets Treatment-Resistant Metastatic Disease

A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.

Clinical Trial
May 29, 2026 0
T-VEC Plus Pembrolizumab Tested in Melanoma After Anti-PD-1 Failure
Cancer Research

T-VEC Plus Pembrolizumab Tested in Melanoma After Anti-PD-1 Failure

Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.

Clinical Trial
May 29, 2026 0
Triple Immunotherapy Combo for Recurrent SCLC Terminated After Enrolling 9 Patients
Cancer Research

Triple Immunotherapy Combo for Recurrent SCLC Terminated After Enrolling 9 Patients

A phase I/II trial combining nivolumab, ipilimumab, and lurbinectedin for relapsed SCLC was terminated early, raising questions about feasibility.

Clinical Trial
May 16, 2026 0
Triple Immune Checkpoint Blockade Tested in Advanced Solid Tumors
Cancer Research

Triple Immune Checkpoint Blockade Tested in Advanced Solid Tumors

A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.

Clinical Trial
May 20, 2026 0
Immunotherapy Before Surgery Shows Promise for Advanced Melanoma Treatment
Cancer Research

Immunotherapy Before Surgery Shows Promise for Advanced Melanoma Treatment

Phase II trial tests checkpoint inhibitors given before surgery to shrink tumors and improve outcomes in stage III-IV melanoma patients.

Clinical Trial
Mar 28, 2026 0
Turin Study Maps Why Multiple Myeloma Escapes Anti-CD38 Immunotherapy
Cancer Research

Turin Study Maps Why Multiple Myeloma Escapes Anti-CD38 Immunotherapy

Italian researchers track genomic and cellular changes in myeloma patients to uncover why anti-CD38 treatments stop working.

Clinical Trial
Jun 16, 2026 0
Pfizer Terminates Phase 1 Trial of Novel Anti-PD-1/IL-15 Fusion Protein in Solid Tumors
Cancer Research

Pfizer Terminates Phase 1 Trial of Novel Anti-PD-1/IL-15 Fusion Protein in Solid Tumors

Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.

Clinical Trial
May 14, 2026 0
Page 1 of 2Next